Pfizer's Bosulif, or bosutinib, failed to win approval from the U.K. National Institute for Health and Care Excellence as a treatment for chronic myeloid leukemia. NICE CEO Andrew Dillon said the drugmaker offered insufficient evidence of the drug's efficacy against CML, which prevented the institute from making a clear comparison of the drug's estimated effect on overall survival as compared to other medications.

Related Summaries